RogerJWaltzmanMDMBA

Oncology • Jersey City, NJ

Hematologic Oncology, Complementary and Integrative

Chief Medical Officer, Molecular Templates

Join to view full profile

Dr. Waltzman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Waltzman's full profile

Already have an account?

Office
Molecular Templates
185 Hudson Street, Suite 1510
Jersey City, NJ 07311
Phone+1 862-204-4860

Education & Training

Columbia Business SchoolMBA, Business, 2004 - 2006
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
The Warren Alpert Medical School of Brown UniversityClass of 1992

Certifications & Licensure

CA State Medical License 1998 - 2026
NY State Medical License 1995 - 2026
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

1294 citations
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire N. Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger J. Waltzman
The New England Journal of Medicine. 2012-02-29
106 citations
Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy
Ann Wexler, Anthony M. Berson, Stephen E. Goldstone, Roger J. Waltzman, Jason R. Penzer
Diseases of the Colon and Rectum. 2008-01-01
295 citations
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco, Benjamin N. Ostendorf, Bernardo S. Reis
Cell. 2018-02-08

Abstracts/Posters

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ...
Roger Waltzman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

MT-5111: A novel HER2 targeting engineered toxin body in clinical development.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020

Press Mentions

EPS for Molecular Templates, Inc. (MTEM) Expected at $0.16March 7th, 2019
Rgenix Treats First Patient in Phase 1 Trial of RGX-202October 31st, 2018
Rgenix Bags $40M to Advance Cancer Drugs, Including GSK CastoffOctober 9th, 2018
Join now to see all